Surgalign Holdings, Inc. (SRGA)
| Market Cap | 171.75M |
| Revenue (ttm) | 236.08M |
| Net Income (ttm) | -132.19M |
| Shares Out | 73.21M |
| EPS (ttm) | -1.80 |
| PE Ratio | n/a |
| Forward PE | 526.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $2.04 |
| Previous Close | $2.11 |
| Change ($) | -0.07 |
| Change (%) | -3.32% |
| Day's Open | 2.11 |
| Day's Range | 2.02 - 2.11 |
| Day's Volume | 860,859 |
| 52-Week Range | 1.49 - 4.95 |
Commercial launch of ViBone® Moldable, a next generation moldable cellular bone matrix product in the US Commercial launch of ViBone® Moldable, a next generation moldable cellular bone matrix ...
DEERFIELD, Ill., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the applicatio...
Company is working off a solid base, and the balance sheet is clean. The technicals are ultra oversold especially on the long-term chart.
DEERFIELD, Ill., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a leading global pure-play spine company focused on advancing spine surgery and improving patient ou...
DEERFIELD, Ill., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the applicatio...
Updated agreement expands availability of ViBone® Moldable, a next generation moldable cellular bone matrix product Updated agreement expands availability of ViBone® Moldable, a next generatio...
DEERFIELD, Ill., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...
DEERFIELD, Ill., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...
According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.
DEERFIELD, Ill., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...
Acquisition Delivers on Commitment to the Promise of Digital Surgery to Improve Patient Outcomes
Commitment to the Promise of Digital Surgery to Improve Patient Outcomes Commitment to the Promise of Digital Surgery to Improve Patient Outcomes
About SRGA
Surgalign Holdings, a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plas... [Read more...]
| Industry Medical Devices | IPO Date Aug 10, 0200 |
| Stock Exchange NASDAQ | Ticker Symbol SRGA |
Financial Performance
In 2019, SRGA's revenue was $308.38 million, an increase of 9.99% compared to the previous year's $280.36 million. Losses were -$211.64 million, 6,676.9% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for SRGA stock is "Strong Buy." The 12-month stock price forecast is 5.60, which is an increase of 174.51% from the latest price.